News 1 July, 2025Xinnate raises SEK 31 million in oversubscribed share issue 27 June, 2025New Addition to Xinnate’s Board: Dr Per Norlén, MD PhD 23 May, 2025Xinnate announces successful FDA meeting for TCP-25 14 January, 2025Xinnate receives Orphan Drug Designation from US FDA for TCP-25 17 December, 2024Xinnate AB partners with Destum Partners, Inc. a leading global, advisory firm 27 September, 2024Phase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis Bullosa 5 September, 2024Xinnate presents TCP-25 data at international dermatology congress 7 May, 2024Xinnate reports positive results from Phase 1 study with TCP-25, in patients with Epidermolysis Bullosa 18 March, 2024Xinnate completes Phase 1a/b study with TCP-25
